NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga)
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33651520 |
| Region | North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West, Scotland, Northern Ireland |
| Procedure | limited |
| OCID | ocds-h6vhtk-02baf3 |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| Octapharma Limited | · | · | active |
description
NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga). The framework will commence on 1 June 2021 for a period of 7 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months. Total maximum framework agreement including extension options will be no more than 13 months.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 11 Jun 2021 | Voluntary ex-ante transparency (F15) | Earlier regulations | 013184-2021 |
more from The NHS Commissioning Board (operating under the name of NHS England)
- Implementation of GP referral pathway to NHS CPCS · £1,700,000 · 12 May 2022
- NHS England and NHS Improvement - Independent Clinical Reviews into Deaths in Custody – South East Health & Justice, Detained Estates · 29 Apr 2022
- Provision of Benchmarking Performance Against the Learning Disability Improvement Standards for NHS Trusts · £800,000 · 18 Mar 2022
- PMO Support for the Cancer Healthcare and AI in Health and Care Programmes · £2,000,000 · 3 Mar 2022
- NHS Framework for the North of England, Branded Medicine · £863,999,552 · 1 Mar 2022
- NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual · £216,078,796 · 22 Feb 2022
- NHS National Generic Pharmaceuticals Wave 13 · £1,637,875,080 · 14 Jan 2022
- Targeted Lung Health Check Programme: External Quality Assurance of Radiologists · £800,000 · 22 Dec 2021
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin · NHS England · £1,200,000,000
- NHS Framework Agreement for the supply of Human Immunoglobulin and Anti-D Immunoglobulin · NHS ENGLAND
- SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT) · Ministry of Defence
- SARS-CoV-2 Nucleocapsid proteins for LFT Revalidation and Testing · UK Health Security Agency · £500,000
- CMU Framework for the supply of Anti-D Immunoglobulin · University Hospitals of Leicester NHS Trust · £209,801
- PHE_Scientific Provision for purchase of the Euroimmun Anti SARS CoV 2 IgG assay · Public Health England · £158,400
- 1LHE Goods - Antibodies · NEWCASTLE UNIVERSITY · £25,115
- Contract for the provision of a Homecare Delivery Service for Immunoglobulins · The Newcastle upon Tyne Hospitals NHS Foundation Trust · £5,600,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.